BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15736475)

  • 21. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
    Parulekar W; de Marsh RW; Wong R; Mendenhall W; Davey P; Zlotecki R; Berry S; Rout WR; Bjarnason GA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1487-95. PubMed ID: 15050328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
    Oliva C; Bergnolo P; Inguì M; Bianco L; Pochettino P; Cutin SC; Boglione A; Dal Canton O; Garetto F; Comandone A
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):411-7. PubMed ID: 19727815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
    Deprés-Brummer P; Berthault-Cvitkovic F; Lĕvi F; Brienza S; Vannetzel JM; Jasmin C; Misset JL
    J Infus Chemother; 1995; 5(3 Suppl 1):144-7. PubMed ID: 8528975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
    Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
    Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
    Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
    Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.